Johnson & Johnson (NYSE: JNJ) has informed investors that the final overall survival (OS) analysis from its Phase 3 PAPILLON study in non-small cell lung cancer (NSCLC) will be featured in a presidential symposium at the upcoming World Conference on Lung Cancer. However, the company has not yet disclosed the actual results, leaving the market in suspense over a key efficacy endpoint.
The announcement, made in a September 11 preview, confirms that the final analysis of Rybrevant (amivantamab) plus chemotherapy will be presented as a late-breaking abstract. Yet, no hazard ratio, median survival, confidence interval, or statistical significance was provided. This update is a data-calendar event, not an efficacy readout.
Background of the PAPILLON Trial
PAPILLON enrolled 308 previously untreated patients with advanced NSCLC harboring EGFR exon 20 insertion mutations. In the initial analysis published in the New England Journal of Medicine, the addition of Rybrevant to carboplatin and pemetrexed improved median progression-free survival (PFS) to 11.4 months from 6.7 months, with a hazard ratio for progression or death of 0.40—a substantial and statistically significant benefit.
However, the interim overall survival data were less definitive. At 33% data maturity, the hazard ratio for death was 0.67, but the 95% confidence interval spanned 0.42 to 1.09, and the P value was 0.11, indicating a favorable trend that did not reach conventional statistical significance. The final analysis is therefore expected to clarify whether the survival benefit is real.
Interpreting the Final Data
One complicating factor is the high crossover rate: after disease progression, 66% of patients initially assigned to chemotherapy received Rybrevant monotherapy. This crossover can narrow the observed survival difference between treatment arms, making the final hazard ratio potentially more modest than the PFS benefit. Investors will need to assess the final OS result in the context of the crossover and confidence interval, rather than simply looking at the word "final."
Rybrevant already holds regulatory approval in this setting. The FDA approved the combination with chemotherapy as a first-line treatment in March 2024 based on PFS data. Mature survival data could strengthen the drug's clinical differentiation, support guideline recommendations, and help J&J defend its market position against competitors.
Commercial Impact
The Rybrevant franchise is growing rapidly from a small base. In the second quarter, worldwide sales of Rybrevant and Lazcluze (lazertinib) reached $289 million, up 60.8% year-over-year. First-half sales totaled $546 million, a 70.4% increase. Despite this growth, the combination represented only about 1.1% of J&J's $25.3 billion quarterly revenue, so the readout is significant for one of the company's fastest-growing oncology assets, but not a make-or-break event for the entire company.
Safety remains a key consideration. The current release notes that serious adverse reactions occurred in 37% of PAPILLON patients on the Rybrevant combination, with fatal adverse reactions in seven patients (4.6%). J&J is also presenting data on subcutaneous Rybrevant Faspro and preventive strategies to improve tolerability, but these should be evaluated separately from the survival endpoint.
Market Reaction
JNJ shares closed at $265.58 on September 11, down 0.29%, reflecting a muted response to the announcement. The market is waiting for the actual numbers. When the presentation occurs, key metrics to watch include the OS hazard ratio, its confidence interval, median survival in each arm, and the impact of crossover. Until then, the only fact is that final data are coming; the conclusion that the trial improved survival remains unproven.
